Kingswood Wealth Advisors LLC Sells 27,208 Shares of Novo Nordisk A/S (NYSE:NVO)

Kingswood Wealth Advisors LLC reduced its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 75.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,822 shares of the company's stock after selling 27,208 shares during the period. Kingswood Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $759,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of NVO. Xponance Inc. raised its position in shares of Novo Nordisk A/S by 27.6% in the second quarter. Xponance Inc. now owns 2,665 shares of the company's stock worth $380,000 after acquiring an additional 576 shares during the period. AQR Capital Management LLC lifted its stake in Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company's stock worth $2,450,000 after acquiring an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Novo Nordisk A/S by 2.2% in the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company's stock valued at $18,824,000 after purchasing an additional 2,817 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Novo Nordisk A/S by 9.5% during the second quarter. Cetera Investment Advisers now owns 290,845 shares of the company's stock worth $41,515,000 after purchasing an additional 25,307 shares during the last quarter. Finally, New Century Financial Group LLC acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $247,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 2.0 %

NVO stock traded up $1.71 during mid-day trading on Thursday, hitting $85.74. The stock had a trading volume of 3,862,657 shares, compared to its average volume of 9,529,480. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a fifty day moving average of $94.32 and a 200 day moving average of $113.82. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $384.77 billion, a price-to-earnings ratio of 27.74, a PEG ratio of 0.90 and a beta of 0.45.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.